- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00242879
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
May 25, 2017 updated by: ViiV Healthcare
Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
This is a two phase study (randomised and non-randomised phase).
The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an ongoing, open-labeled rtv-boosted protease inhibitor (PI) regimen for 15 days.
At the Day 15 visit, all subjects will optimize background therapy.
Additionally, subjects receiving the lowest dose of GW640385 will be re-randomised to one of the higher doses and subjects in the control arm will receive a new rtv-boosted PI based on resistance testing at screening.
Subjects will remain in the randomized phase on one of these 4 continuing treatment arms for at least 48 weeks.
An interim analysis will occur during the randomised phase to select for a dose of GW640385 to evaluate further in Phase III studies.
After dose selection subjects will move to the non-randomised phase of the study.
In the non-randomised phase subjects who are receiving GW640385 will be assigned to final selected dose for assessment of long term safety, tolerability, pharmacokinetics, and antiviral activity.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, PK and Antiviral Activity of Four Dosing Regimens of GW640385/rtv Therapy Compared to Open-label Current Protease Inhibitor (PI) Therapy in HIV-1, PI-Experienced Adults for 2 wks with Long-Term Evaluation (>48 wks) of Safety, PK and Antiviral Activity of Selected GW640385/rtv Dosing Regimen(s) vs. a RTV-boosted, PI Containing Regimen
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- GSK Investigational Site
-
Liverpool, New South Wales, Australia, 2170
- GSK Investigational Site
-
-
Victoria
-
South Yarra, Victoria, Australia, 3141
- GSK Investigational Site
-
-
-
-
-
Bruxelles, Belgium, 1000
- GSK Investigational Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2C7
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5B 1L6
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4P9
- GSK Investigational Site
-
Montreal, Quebec, Canada, H2X 2P4
- GSK Investigational Site
-
Sainte-Foy, Quebec, Canada, G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Caen, France, 14000
- GSK Investigational Site
-
La Roche Sur Yon cedex 9, France, 85025
- GSK Investigational Site
-
Lyon Cedex 02, France, 69288
- GSK Investigational Site
-
Lyon Cedex 03, France, 69437
- GSK Investigational Site
-
Nantes, France, 44093
- GSK Investigational Site
-
Paris Cedex 10, France, 75475
- GSK Investigational Site
-
Paris Cedex 12, France, 75571
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 13353
- GSK Investigational Site
-
Hamburg, Germany, 20099
- GSK Investigational Site
-
-
Bayern
-
Muenchen, Bayern, Germany, 80335
- GSK Investigational Site
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53127
- GSK Investigational Site
-
Essen, Nordrhein-Westfalen, Germany, 45122
- GSK Investigational Site
-
-
-
-
Emilia-Romagna
-
Ferrara, Emilia-Romagna, Italy, 44100
- GSK Investigational Site
-
Rimini, Emilia-Romagna, Italy, 47900
- GSK Investigational Site
-
-
Lombardia
-
Milano, Lombardia, Italy, 20127
- GSK Investigational Site
-
Pavia, Lombardia, Italy, 27100
- GSK Investigational Site
-
-
Piemonte
-
Torino, Piemonte, Italy, 10149
- GSK Investigational Site
-
-
Puglia
-
Bari, Puglia, Italy, 70124
- GSK Investigational Site
-
-
Toscana
-
Bagno a Ripoli (FI), Toscana, Italy, 50126
- GSK Investigational Site
-
-
-
-
-
Cascais, Portugal, 2750
- GSK Investigational Site
-
Lisboa, Portugal, 1150
- GSK Investigational Site
-
-
-
-
-
Ponce, Puerto Rico, 00731
- GSK Investigational Site
-
San Juan, Puerto Rico, 00909-1711
- GSK Investigational Site
-
-
-
-
-
Bucharest, Romania, 021105
- GSK Investigational Site
-
Constanta, Romania, 900709
- GSK Investigational Site
-
Iasi, Romania, 700116
- GSK Investigational Site
-
-
-
-
-
London, United Kingdom, EC1 7BE
- GSK Investigational Site
-
London, United Kingdom, SW10 9TH
- GSK Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- GSK Investigational Site
-
-
California
-
Bakersfield, California, United States, 93301
- GSK Investigational Site
-
Fountain Valley, California, United States, 92708
- GSK Investigational Site
-
Los Angeles, California, United States, 90046
- GSK Investigational Site
-
San Francisco, California, United States, 94115
- GSK Investigational Site
-
San Francisco, California, United States, 94121
- GSK Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80204
- GSK Investigational Site
-
Denver, Colorado, United States, 80220
- GSK Investigational Site
-
-
Connecticut
-
Norwalk, Connecticut, United States, 06851
- GSK Investigational Site
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20007
- GSK Investigational Site
-
Washington, D.C., District of Columbia, United States, 20009
- GSK Investigational Site
-
-
Florida
-
Bradenton, Florida, United States, 34205
- GSK Investigational Site
-
Fort Lauderdale, Florida, United States, 33316
- GSK Investigational Site
-
Fort Lauderdale, Florida, United States, 33306
- GSK Investigational Site
-
Fort Lauderdale, Florida, United States, 33308
- GSK Investigational Site
-
Miami Beach, Florida, United States, 33140
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612-7230
- GSK Investigational Site
-
Chicago, Illinois, United States, 60613
- GSK Investigational Site
-
Chicago, Illinois, United States, 60657
- GSK Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- GSK Investigational Site
-
Boston, Massachusetts, United States, 02118
- GSK Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- GSK Investigational Site
-
-
New Jersey
-
Newark, New Jersey, United States, 7102
- GSK Investigational Site
-
-
New York
-
Rochester, New York, United States, 14604
- GSK Investigational Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75246
- GSK Investigational Site
-
Houston, Texas, United States, 77027
- GSK Investigational Site
-
-
Virginia
-
Hampton, Virginia, United States, 23666
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- 18+ years of age (or =16 years of age for non-EU countries, according to local requirements).
- HIV-1 infected subjects.
- Females must be of either non-childbearing potential or have a negative pregnancy test at Screening and agree to use a protocol approved method of contraception.
- Plasma HIV-1 RNA (viral load) =1,000 copies/mL at Screening.
- Evidence of at least 2 multi-PI resistant mutations at Screening or within 3 months of Screening.
- Subjects must have been receiving the same anti-HIV medicines that they are on currently for at least 8 weeks prior to Screening; these anti-HIV medicines will include a single protease inhibitor (PI) in combination with a low dose of ritonavir (i.e., a ritonavir-boosted PI). However, the current PI cannot be tipranavir.
- Able to understand and follow protocol requirements, instructions and protocol-stated restrictions.
- Be willing and able to provide signed and dated written informed consent prior to study entry.
Exclusion criteria:
- Subjects cannot change their anti-HIV medicines between Screening and Day 1 Visit.
- Subjects can not be receiving dual ritonavir-boosted PIs, non-nucleoside reverse transcriptase inhibitors (NNRTIs) or Tipranavir at Screening.
- Active CDC Class C disease at screening.
- Pregnant or breastfeeding women.
- Protocol-specified laboratory abnormalities at Screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Time averaged change in plasma HIV-1 RNA over 16 wks
|
Proportion of subjects achieving the target pharmacokinetic (PK) GW640385 drug levels
|
Change in laboratory parameters
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessments of HIV viral load changes
|
GW640385 and RTV pharmacokinetic measurements
|
The incidence of adverse events
|
Changes in laboratory measurements
|
ECG measurements
|
HIV viral resistance assessment
|
Immunologic measures
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
October 19, 2005
First Submitted That Met QC Criteria
October 19, 2005
First Posted (Estimate)
October 21, 2005
Study Record Updates
Last Update Posted (Actual)
May 30, 2017
Last Update Submitted That Met QC Criteria
May 25, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
Other Study ID Numbers
- HPR20001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Physician determined comparator PI + ritonavir
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown
-
National Taiwan University HospitalFar Eastern Memorial HospitalCompleted
-
National Taiwan University HospitalUnknown
-
GlaxoSmithKlineJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1United States, Finland, Sweden, Italy, Spain, United Kingdom, Germany, Canada, Denmark
-
The HIV Netherlands Australia Thailand Research...Ministry of Education, ThailandCompletedHIV Infections | HIV InfectionThailand
-
Catherine ShuCompleted
-
Juan A. ArnaizCompletedHIV | HypercholesterolaemiaSpain
-
Janssen-Cilag Ltd.Completed
-
Merck Sharp & Dohme LLCTerminated
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a